Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

✓ Peer-reviewed alzhub usefulness score 50 out of 100. Tau biomarkers

Topic: Amyloid, tau and blood-test diagnosis

Plain-language summary

Immune mechanisms may be important in the pathogenesis of Alzheimer's disease (AD). Yet, studies comparing cerebrospinal fluid (CSF) and plasma immune marker levels of healthy and demented individuals have yielded conflicting results. We analyzed CSF from 101 members of the parental history-positive PREVENT-AD cohort of healthy aging adults, and 237 participants without dementia from the initial cohort of the Alzheimer's Disease Neuroimaging Initiative (ADNI-1).

What this study adds

Evidence grade: Moderate

The record lists 237 participants. This study analyzed cerebrospinal fluid immune markers in healthy aging adults and in people without dementia, using tau and amyloid biomarkers to stage disease. It is an observational study and does not test any treatment that targets immune mechanisms.

Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Meyer, P. F., Savard, M., Poirier, J., Labonté, A., Rosa-Neto, P., Weitz, T. M., et al. (2018). Bi-directional Association of Cerebrospinal Fluid Immune Markers with Stage of Alzheimer's Disease Pathogenesis. Journal of Alzheimer's disease : JAD. https://doi.org/10.3233/jad-170887

Vancouver

Meyer PF, Savard M, Poirier J, Labonté A, Rosa-Neto P, Weitz TM, et al. Bi-directional Association of Cerebrospinal Fluid Immune Markers with Stage of Alzheimer's Disease Pathogenesis. Journal of Alzheimer's disease : JAD. 2018. doi:10.3233/jad-170887. PMID: 29660934.

BibTeX

@article{meyer2018-29660934,
  author  = {Meyer, P. F. and Savard, M. and Poirier, J. and Labonté, A. and Rosa-Neto, P. and Weitz, T. M. and Town, T. and Breitner, J. and others},
  title   = {{Bi-directional Association of Cerebrospinal Fluid Immune Markers with Stage of Alzheimer's Disease Pathogenesis}},
  journal = {Journal of Alzheimer's disease : JAD},
  year    = {2018},
  doi     = {10.3233/jad-170887},
  pmid    = {29660934},
  url     = {https://doi.org/10.3233/jad-170887}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.

Key findings

Why it matters

This study analyzed cerebrospinal fluid immune markers in healthy aging adults and in people without dementia, using tau and amyloid biomarkers to stage disease. It is an observational study and does not test any treatment that targets immune mechanisms.

Study details

How this study scored 50/100
How this study's score is builtJournal tier 7 of 10; Journal's citation record 2 of 4; Study design 0 of 12; Strength of evidence 3 of 5; Peer-review validation 10 of 10; How recent 2 of 5; Sample size 2 of 4; Effect reported 0 of 3; Studied in people 3 of 3; Randomized / blinded 0 of 2; Times cited 4 of 7; Citations per year 2 of 5; Impact for its field and year 3 of 6; Cited by studies here 2 of 6; Still being cited 1 of 4; Senior author's track record 1 of 4; Institution's track record 2 of 3; Multicenter collaboration 2 of 3; Indexed in PubMed 2 of 2; Free to read 2 of 2. Total 50 of 100.50 of 100 points earned50 not earned

Published in a peer-reviewed journal. Scored zero for study design, effect reported and randomized / blinded because the record does not state it.

ComponentPointsWhy
Journal tier 7 / 10 Tier 3 — peer-reviewed journal (Journal of Alzheimer's disease : JAD)
Journal's citation record 2 / 4 Journal of Alzheimer s Disease: journal h-index 218 (OpenAlex, 2026-10-29)
Study design 0 / 12 No study design recorded — scores zero, not guessed (not stated in the record — scored 0)
Strength of evidence 3 / 5 Rated “moderate” in our summary
Peer-review validation 10 / 10 Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent 2 / 5 2018 — within 10 year(s) of the newest study here
Sample size 2 / 4 237 participants
Effect reported 0 / 3 No effect size reported — scores zero (not stated in the record — scored 0)
Studied in people 3 / 3 Studied in people (participant count stated)
Randomized / blinded 0 / 2 No randomization or blinding stated — scores zero (not stated in the record — scored 0)
Times cited 4 / 7 Cited 44 times (OpenAlex, 2026-10-10)
Citations per year 2 / 5 4.4 citations a year over 10 year(s) since 2018
Impact for its field and year 3 / 6 Cited 3.3× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here 2 / 6 Cited by 4 other studies in this library
Still being cited 1 / 4 Cited 9 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record 1 / 4 Last-listed author for the Alzheimer’s Disease Neuroimaging Initiative: h-index 12 (OpenAlex, whole career)
Institution's track record 2 / 3 University of Southern California: institution h-index 1,521 (OpenAlex)
Multicenter collaboration 2 / 3 OpenAlex lists 4 institution(s) in 2 countries
Indexed in PubMed 2 / 2 Indexed in PubMed (PMID 29660934)
Free to read 2 / 2 Free to read
Total 50 / 100 —

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).

Studies in the library that share something with this one. The line above each title says what.

Studies this one cites

Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 19.

Later studies that cite this one

4 studies in the alzhub library list this one in their references.

Related studies in Tau biomarkers from nearby years

Also tagged “cerebrospinal”

820 studies in the library carry the topic tag “cerebrospinal”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 820 tagged studies.

Studies sharing this one's topic tags

Similar studies

More on Tau biomarkers

See all studies in Tau biomarkers →